Tag: chief executive officer

CALGARY, Alberta, June 13, 2025 (GLOBE NEWSWIRE) -- PHX Energy Services Corp. ("PHX Energy" or the "Corporation") is pleased to announce that its Board of Directors has declared a quarterly cash dividend of $0.20 per common share designated as an “eligible dividend” within the meaning of subsection 89(1) of the Income Tax Act (Canada), payable on July 15, 2025, to shareholders of record at the close of business on June 30, 2025.

CHENGDU, China, June 13, 2025 (GLOBE NEWSWIRE) -- Senmiao Technology Limited (“Senmiao” or the “Company”) (Nasdaq: AIHS), a financing and servicing company focused on the online ride-hailing industry in China, today announced that it has signed a strategic cooperation agreement (the “Agreement”) with Changsha Yipeng Information Technology Co., Ltd. (“Changsha Yipeng”) to jointly develop an AI-backed data management system aiming to improve efficiency of online ride-hailing management platforms.

New clinical results show sustained CRi, deep bone marrow responses, and encouraging survival in FLT3-mutant AML patients, including those previously treated with gilteritinib

MISSISSAUGA, Ontario, June 12, 2025 (GLOBE NEWSWIRE) -- On Tuesday June 11, Alectra employees participated in YWCA Hamilton’s “Walk a Mile in Their Shoes”, annual event, raising more than $10,000 to support efforts to end gender-based violence. The event brings together community members in a symbolic walk to raise vital funds and awareness for survivors and the programs that support them.

Hapbee Also Updates Status of Audited Financial Statements

Châtillon, France, June 12, 2025

PARAMUS, N.J., June 12, 2025 (GLOBE NEWSWIRE) -- Starton Therapeutics Inc. (“Starton”), a clinical-stage biotechnology company transforming standard-of-care therapies with proprietary continuous delivery technologies, announced today Gabrail Cancer Center (GCC) in Canton, Ohio is now activated and open for enrolling patients in its Phase 2a clinical trial evaluating their continuous low-dose lenalidomide, STAR-LLD, for the treatment of multiple myeloma (MM). Dr. Nash Gabrail, medical oncologist and founder of the Center, is the study’s lead investigator. Regional Medical Oncology Center, located in Wilson, NC, has also opened as the trial’s second active clinical site.